Biotechnology News and Research

RSS

Allele’s scientists describe important advance in generation of human stem cells

This week in the journal Scientific Reports, scientists from Allele Biotechnology describe an important advance in the generation of stem cells capable of producing all the different tissues of the human body.

15 Sep 2012

UMDNJ, Proteonomix to conduct UMK-121 Phase 1 trial in end-stage liver disease

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has entered into an agreement with Piscataway, N.J.-based University of Medicine and Dentistry of New Jersey (UMDNJ) to conducted a Phase 1 clinical trial with its proprietary, patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD).

15 Sep 2012

First annual Golden Goose Awards honor eight scientists

Eight scientists, including four Nobel Prize winners, will be honored today with the first annual Golden Goose Awards, celebrating researchers whose seemingly odd or obscure federally funded research turned out to have a significant impact on society. The awardees will be honored at a ceremony on Capitol Hill, where they will receive their awards from a bipartisan group of Members of Congress.

15 Sep 2012

Humans could learn from how plants handle stress

Humans could learn from how plants handle stress. Federica Brandizzi, Michigan State University plant biologist, is using a grant from the National Institutes of Health to study how plants overcome stress as they grow. These pathways used to overcome stress are a key to growth. Without them plants, and animals, would die.

14 Sep 2012

Senesco initiates SNS01-T cohort 2 trial in multiple myeloma

Senesco Technologies, Inc. reported today that the first patient has been enrolled and dosing has been initiated in cohort 2 of its clinical trial with SNS01-T in multiple myeloma.

14 Sep 2012

Patheon third quarter revenues increase to $203.7 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today fiscal 2012 third quarter and nine month results.

13 Sep 2012

Synthetic biology pioneer wins 2012 Heinz Award

Jay Keasling, a leading authority and pioneer on synthetic biology who has engineered microbial "factories" to manufacture an affordable version of a frontline antimalarial drug and biofuel substitutes for gasoline, diesel and jet fuel, has won a 2012 Heinz Award, which is presented by the Heinz Family Foundation and carries with it a cash prize of $250,000.

13 Sep 2012

ATA, AACE develop new guidelines for diagnosis and treatment of hypothyroidism

New evidence-based guidelines have been released for the diagnosis and treatment of hypothyroidism, a complex disease caused by an underactive thyroid gland that cannot produce enough thyroid hormone.

13 Sep 2012

Data from Oncolytics’ REOLYSIN Phase III combination trial on head and neck cancers

Oncolytics Biotech Inc. today provided an update on its Phase III trial of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of head and neck cancers (REO 018).

12 Sep 2012

Molecular beacons allow scientists to monitor gene expression during stem cell transformation

A novel set of custom-designed "molecular beacons" allows scientists to monitor gene expression in living populations of stem cells as they turn into a specific tissue in real-time. The technology, which Brown University researchers describe in a new study, provides tissue engineers with a potentially powerful tool to discover what it may take to make stem cells transform into desired tissue cells more often and more quickly.

12 Sep 2012

Bruker launches BioPharmaCompass 1.1 software

At the 2012 CASSS 9th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry, Bruker today launches the first software solution to encompass the complete biopharmaceutical characterization challenge, including glycoforms, impurities and modifications.

From Bruker BioSpin Group 12 Sep 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

12 Sep 2012

Scripps scientists discover new antibody-discovery technique

Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses. New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.

12 Sep 2012

Palatin fourth quarter revenues decrease to $11,000

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012.

11 Sep 2012

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of two major grants for the development of monoclonal antibody therapeutics against nosocomial infections.

11 Sep 2012

First demonstration of newly developed dual humanized FRGTM KO system against malaria

A novel human liver-chimeric mouse model developed at Oregon Health & Science University and Yecuris Corporation has made possible a research breakthrough at Seattle Biomedical Research Institute that will greatly accelerate studies of the most lethal forms of human malaria.

11 Sep 2012

Rhode Island receives NIH grant to study cartilage and joint health

Rhode Island Hospital's Center of Biomedical Research Excellence (COBRE) in Skeletal Health and Repair has been awarded a $10.8 million grant from the National Institutes of Health (NIH), one of the largest grants in Rhode Island Hospital history. This grant, to be paid over five years, will fund studies of cartilage and joint health.

11 Sep 2012

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).

11 Sep 2012

Annovation Biopharma to develop novel anesthetics with $8M Series A financing

Annovation Biopharma, a biotechnology company focused on creating more effective, safer therapies for anesthesia and critical care, has raised $8M in a Series A financing led by Atlas Venture, Partners Innovation Fund, and new strategic investor The Medicines Company.

10 Sep 2012

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital. This technology is complimentary to the early Beta cell destruction diagnostic that Islet Sciences licensed last month.

10 Sep 2012